GTB-360

Phase 1Small molecule

MMasonic Cancer Center, University of Minnesota

GTB-360 is one of 2 small molecule programs targeting Myeloid Malignancy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid MalignancyRecruiting

Myeloid MalignancyPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Myeloid Malignancy

#DrugCompanyPhaseTrials

IFN-α

PPeking University People's Hospital

Phase 2

1 2

GTB-360

MMasonic Cancer Center, University of Minnesota

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Myeloid Malignancy

NCT06594445

Clinical

Trials by Indication[1]

Myeloid Malignancy1 trial

HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT06594445·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GTB-360. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GTB-360 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GTB-360. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMasonic Cancer Center, University of Minnesota

GTB-360

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Myeloid Malignancy1 trial

References

Drug Info

Quick Facts

Related News